Actualités

A federal appeals court ruled Thursday that international versions of Gilead's HIV drug Biktarvy differ materially from FDA-regulated U.S. versions

Picture three students turning in exams on the same day, covering the same material. Two walk away with high marks. The third has been raising his grades all semester, yet still gets flagged for summer school. That is roughly the dynamic inside the BofA research note on biotech I received on the ...

By Deena Beasley Aug 4 (Reuters) - Gilead Sciences on Tuesday reported second-quarter product sales rose 8%, led by double-digit gains for its HIV drugs, but it posted a quarterly loss due to costs

US equities rallied intraday, fueled by upbeat earnings reports and hopes that the Strait of Hormuz

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]

U.S. Food and Drug Administration (FDA) approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus.

Spiking energy prices have pushed inflation to a three-year high of 3.8%. Investors expect price pressures related to the Iran war to ease—one reason the stock market keeps chugging along. Retirees who collect Social Security should get a bigger raise next year.